Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly (FENTA)
Primary Purpose
Pain Due to Certain Specified Procedures
Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
intranasal fentanyl
Sponsored by
About this trial
This is an interventional treatment trial for Pain Due to Certain Specified Procedures focused on measuring safety, procedural pain, intranasal fentanyl, elderly
Eligibility Criteria
Inclusion Criteria:
- Hospitalized geriatric patient requiring care or rehabilitation
- Patient with pain during treatment or mobilization. (VAS ≥ 4)
- Written Informed consent
Exclusion Criteria:
- All unstable fractures
- Confusion: unable to assess their level of pain using a VAS.
- Contraindications to PecFent ® (. Hypersensitivity to the active substance or to any of the excipients listed in section Composition Use in patients who had never received treatment for opioid severe respiratory depression or severe obstructive pulmonary disease.)
- Person under legal protection
Sites / Locations
- University hospital of Grenoble
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Intranasal fentanyl
Arm Description
Outcomes
Primary Outcome Measures
Safety of intranasal fentanyl as measured by the nature and frequency of adverse effects.
The nature and frequency of adverse effects will be described. The collection of adverse events will be first, with the collection of spontaneous patient complaints from nurses on the other hand, by systematic screening with the patient. Monitoring of respiratory rate and level of sedation will also be set up.
Secondary Outcome Measures
Effectiveness of intranasal fentanyl in procedural pain using a VAS (Visual Analogic Scale) of pain.
VAS will be evaluated during each session at t0, t0+15min, t0+30min, and 1hour after the session (on average at 2 hours)
Fentanyl impact on the goals of care as measured by a caregiver satisfaction scale.
At the end of each session of care or rehabilitation, it will be proposed to the caregiver, a scale measuring its satisfaction regarding the objectives achieved during the session.
Nurse or physiotherapist satisfaction regarding use of PecFent® as measured by a verbal descriptor scale
Nurse or physiotherapist evaluation satisfaction regarding the convenience of the use of pecfent® and its contribution towards care using a verbal descriptor scale
Impact of PecFent® on patient feelings during care or rehabilitation sessions as measured by a verbal descriptor scale
Patient evaluation at the end of sessions:
- Patient satisfaction regarding the course of the session with a VDS
Full Information
NCT ID
NCT02298582
First Posted
October 13, 2014
Last Updated
May 2, 2018
Sponsor
University Hospital, Grenoble
1. Study Identification
Unique Protocol Identification Number
NCT02298582
Brief Title
Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly
Acronym
FENTA
Official Title
Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly With or Without Background Treatment.
Study Type
Interventional
2. Study Status
Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
December 8, 2014 (Actual)
Primary Completion Date
October 24, 2017 (Actual)
Study Completion Date
April 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Grenoble
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety of the intranasal fentanyl in pain induced by wound care and rehabilitation in the elderly. The project would also provide a preliminary assessment of the effectiveness of intranasal fentanyl used in procedural pains.
Detailed Description
This is a safety clinical trial. This trial is monocentric, open label, non-randomized.
Sixty elderly patients will be enrolled in this study, 30 with bedsore cares and 30 with rehabilitation sessions.
Six bedsore cares or rehabilitation sessions will be assessed for each subject. For each session, patient pain will be evaluated using a visual analogic scale VAS at different times, before session, 5 minutes then 20 minutes after the beginning of the session, and a last VAS 1 hour after the end of the session. During the two first sessions, patients do not receive Pecfent® to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care.
An evaluation of respiratory rate and of the level of sedation will occur at different time : after 5 minutes then 20 minutes of care, at the end of the care session,at half an hour then one hour after the care session.
At the end of sessions,
The nurse or physiotherapist will assess their satisfaction regarding the objectives achieved during the session with a four points verbal descriptor scale (very satisfied, satisfied, not much satisfied, not satisfied). They will also evaluate at the end of the four last session their satisfaction regarding the convenience of the use of pecfent® and its contribution towards care.
Patients will assess their satisfaction regarding the course of the session with a verbal descriptor scale (VDS) and their level of anxiety felt during the session with a VAS.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain Due to Certain Specified Procedures
Keywords
safety, procedural pain, intranasal fentanyl, elderly
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
58 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intranasal fentanyl
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
intranasal fentanyl
Intervention Description
During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session
Primary Outcome Measure Information:
Title
Safety of intranasal fentanyl as measured by the nature and frequency of adverse effects.
Description
The nature and frequency of adverse effects will be described. The collection of adverse events will be first, with the collection of spontaneous patient complaints from nurses on the other hand, by systematic screening with the patient. Monitoring of respiratory rate and level of sedation will also be set up.
Time Frame
5 days after the last intake of fentanyl.
Secondary Outcome Measure Information:
Title
Effectiveness of intranasal fentanyl in procedural pain using a VAS (Visual Analogic Scale) of pain.
Description
VAS will be evaluated during each session at t0, t0+15min, t0+30min, and 1hour after the session (on average at 2 hours)
Time Frame
Evolution of the level of pain (VAS) since the beginning of care until one hour after the end of session (on average at 2 hours).
Title
Fentanyl impact on the goals of care as measured by a caregiver satisfaction scale.
Description
At the end of each session of care or rehabilitation, it will be proposed to the caregiver, a scale measuring its satisfaction regarding the objectives achieved during the session.
Time Frame
At the end of session of care or rehabilitation (on average at 1 hour).
Title
Nurse or physiotherapist satisfaction regarding use of PecFent® as measured by a verbal descriptor scale
Description
Nurse or physiotherapist evaluation satisfaction regarding the convenience of the use of pecfent® and its contribution towards care using a verbal descriptor scale
Time Frame
1 hour after the last intake of fentanyl
Title
Impact of PecFent® on patient feelings during care or rehabilitation sessions as measured by a verbal descriptor scale
Description
Patient evaluation at the end of sessions:
- Patient satisfaction regarding the course of the session with a VDS
Time Frame
At the end of Session of care or rehabilitation (on average at 1 hour).
10. Eligibility
Sex
All
Minimum Age & Unit of Time
76 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Hospitalized geriatric patient requiring care or rehabilitation
Patient with pain during treatment or mobilization. (VAS ≥ 4)
Written Informed consent
Exclusion Criteria:
All unstable fractures
Confusion: unable to assess their level of pain using a VAS.
Contraindications to PecFent ® (. Hypersensitivity to the active substance or to any of the excipients listed in section Composition Use in patients who had never received treatment for opioid severe respiratory depression or severe obstructive pulmonary disease.)
Person under legal protection
Facility Information:
Facility Name
University hospital of Grenoble
City
Grenoble
State/Province
Isere
ZIP/Postal Code
38043
Country
France
12. IPD Sharing Statement
Learn more about this trial
Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly
We'll reach out to this number within 24 hrs